Revolution Medicines Inc.: Truist recommends buying with 154% price potential!
Reading Time: 3 minutes
Revolution Medicines Inc. (RVMD) is a biopharmaceutical company focused on developing novel, targeted therapies for patients with RAS-dependent cancers. The company’s pipeline is based on so-called RAS(ON) inhibitors aimed at suppressing various oncogenic variants of RAS proteins. The focus is particularly on the three main clinical candidates: Daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, Elironrasib (RMC-6291), a selective G12C inhibitor, and Zoldonrasib (RMC-9805), a selective G12D inhibitor. The company is also developing additional...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
